<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152385</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00016</org_study_id>
    <nct_id>NCT01152385</nct_id>
  </id_info>
  <brief_title>Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect on glucose control of 3 different AZD1656
      dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as
      evaluated by the change in HbA1c from baseline to the end of treatment at 4 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Haemoglobin A1c (HbA1c)</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders in Terms of HbA1C ≤ 7%</measure>
    <time_frame>at 4th month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders in Terms of HbA1C ≤ 6.5%</measure>
    <time_frame>at 4th month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Triglycerides</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>from baseline to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Oral tablet administered twice daily during 4 months</description>
    <arm_group_label>high</arm_group_label>
    <arm_group_label>Middle</arm_group_label>
    <arm_group_label>low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered twice daily during 4 months</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women of non-childbearing potential.

          -  Provision of informed consent prior to any study specific procedures

          -  Naïve T2DM patients with HbA1c ≥ 7.5% but ≤ 10% or T2DM Patients treated with one or
             two oral anti-hyperglycaemic agent(s) with HbA1c ≥ 7.5% but ≤ 9.5% at enrolment visit
             (Visit1)

        Exclusion Criteria:

          -  Clinically relevant medical history or concurrent disease such as cardiovascular
             disease, renal disease, hepatic disease and haematological disease.

          -  The investigator(s) judged that the Subject should not participate in the study
             according to screening test or medical history.

          -  Participation in another clinical trial and/or intake of another investigational drug
             within the last 30 days prior to enrolment visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Leonsson-Zachrisson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <results_first_submitted>July 24, 2012</results_first_submitted>
  <results_first_submitted_qc>July 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Japanese</keyword>
  <keyword>phase 2</keyword>
  <keyword>AZD1656</keyword>
  <keyword>efficacy</keyword>
  <keyword>dose regimen</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment: 224 Study Start Date: May 2010 Study Completion Date: May 2011 Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)</recruitment_details>
      <pre_assignment_details>Wash-out period for patients treated with anti-diabetes treatment at enrolment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>200 mg (daily dose)</description>
        </group>
        <group group_id="P2">
          <title>Middle Dose</title>
          <description>140 mg (daily dose)</description>
        </group>
        <group group_id="P3">
          <title>Low Dose</title>
          <description>80 mg (daily dose)</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>200 mg (daily dose)</description>
        </group>
        <group group_id="B2">
          <title>Middle Dose</title>
          <description>140 mg (daily dose)</description>
        </group>
        <group group_id="B3">
          <title>Low Dose</title>
          <description>80 mg (daily dose)</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                    <measurement group_id="B2" value="55" spread="9"/>
                    <measurement group_id="B3" value="55" spread="10"/>
                    <measurement group_id="B4" value="57" spread="9"/>
                    <measurement group_id="B5" value="56" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Haemoglobin A1c (HbA1c)</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High Dose</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle Dose</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low Dose</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo Dose</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haemoglobin A1c (HbA1c)</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.2"/>
                    <measurement group_id="O2" value="-0.3" spread="1.3"/>
                    <measurement group_id="O3" value="0.1" spread="1.2"/>
                    <measurement group_id="O4" value="0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG)</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High Dose</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle Dose</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low Dose</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo Dose</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG)</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="42"/>
                    <measurement group_id="O2" value="6" spread="45"/>
                    <measurement group_id="O3" value="1" spread="36"/>
                    <measurement group_id="O4" value="16" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders in Terms of HbA1C ≤ 7%</title>
        <time_frame>at 4th month</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders in Terms of HbA1C ≤ 7%</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders in Terms of HbA1C ≤ 6.5%</title>
        <time_frame>at 4th month</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders in Terms of HbA1C ≤ 6.5%</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="19.9"/>
                    <measurement group_id="O2" value="7.7" spread="18.8"/>
                    <measurement group_id="O3" value="4.0" spread="15.6"/>
                    <measurement group_id="O4" value="5.8" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in High-density Lipoprotein Cholesterol (HDL-C)</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in High-density Lipoprotein Cholesterol (HDL-C)</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="18.0"/>
                    <measurement group_id="O2" value="8.7" spread="12.9"/>
                    <measurement group_id="O3" value="11.6" spread="12.7"/>
                    <measurement group_id="O4" value="8.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Triglycerides</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Triglycerides</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="44.0"/>
                    <measurement group_id="O2" value="25.0" spread="58.5"/>
                    <measurement group_id="O3" value="6.7" spread="29.4"/>
                    <measurement group_id="O4" value="18.1" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-sensitivity C-reactive Protein (Hs-CRP)</title>
        <time_frame>from baseline to 4 months</time_frame>
        <population>The analysis population was prior to rescue treatment (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - High</title>
            <description>AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Middle</title>
            <description>AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Low</title>
            <description>AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-sensitivity C-reactive Protein (Hs-CRP)</title>
          <population>The analysis population was prior to rescue treatment (FAS)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="0.138"/>
                    <measurement group_id="O2" value="0.021" spread="0.117"/>
                    <measurement group_id="O3" value="0.033" spread="0.125"/>
                    <measurement group_id="O4" value="-0.007" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>200 mg (daily dose)</description>
        </group>
        <group group_id="E2">
          <title>Middle Dose</title>
          <description>140 mg (daily dose)</description>
        </group>
        <group group_id="E3">
          <title>Low Dose</title>
          <description>80 mg (daily dose)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA14.0">Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema Asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 1625 518062</phone>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

